Document is current
Any future updates will be listed below
-
Authors
Kothari, Cartik
Srivastava, Siddharth
Kousa, Youssef
Izem, Rima
Gierdalski, Marcin
Kim, Dongkyu
Good, Amy
Dies, Kira A.
Geisel, Gregory
Morizono, Hiroki
Gallo, Vittorio
Pomeroy, Scott L.
Garden, Gwenn A.
Guay-Woodford, Lisa
Sahin, Mustafa
Avillach, Paul https://orcid.org/0000-0002-0235-7543
-
Funding
Funding for this research was provided by:
National Institutes of Health (U54 HD090255, U54HD090257, U54 HD083091)
National Center for Advancing Translational Sciences (UL1TR001876)
- License Information
-
More Information
Article History
Received: 10 April 2021
Accepted: 4 March 2022
First Online: 23 March 2022
Declarations
:
: Boston Children’s Hospital IRB-P00029725.
: Not applicable.
: 1. CK has no competing interests to declare.2. SS has received consulting fees from GLG, Guidepoint (which connected to a client, Fortress Biotech), and Novartis.3. YK has no competing interests to declare.4. RI has no competing interests to declare.5. MG has no competing interests to declare.6. DK has no competing interests to declare.7. AG has no competing interests to declare.8. KAD has no competing interests to declare.9. GG has no competing interests to declare.10. HM has no competing interests to declare.11. VG has no competing interests to declare.12. SP has no competing interests to declare.13. GAG has no competing interests to declare.14. LGW has no competing interests to declare.15. MS reports grant support from Novartis, Roche, Biogen, Astellas, Aeovian, Bridgebio, Aucta, and Quadrant Biosciences. He has served on Scientific Advisory Boards for PTEN Research, Novartis, Roche, Celgene, Regenxbio, Alkermes, and Takeda.16. PA has no competing interests to declare
